It is expected that general surgeons will soon be in short supply. And this could be as soon as two years’ time. General surgeons are the ones who perform interventions in the emergency room, interventions which save lives. A shortage of these medical professionals would mean even longer waiting time at the ER. And why the shortage? Specialization and the fact that workload wear out doctors fast. We all love hospital dramas from ER to Grey’s Anatomy to Dr. House. A general surgeon’s life can be much harder that what is shown on TV, without the romance and the glamour.
CVD Obesity News
This audio podcast by the Agency for Healthcare Research and Quality (AHQR) gives a nice overview about the problem of obesity and what we can do to prevent it. Join AHQR Director Dr. Carolyn Clancy for this Healthcare 411 podcast.
CVD Pharma News
Remember the diabetic Avandia (rosiglitazone) and the publication leak story? The Wall Street Journal (WJS) obtained internal emails indicating that researchers at the drug manufacturer GlaxoSmithKline (GSK) had already concerns about the drug’s cardiovascular effect even before the story broke out. GSK claims says “it did not attempt to conceal its own meta-analysis showing similar trends as the study by Nissen and Wolski” which publicly pointed out the health risks of the drug. The US FDA has decided to keep the drug in the market while it is still analysing the data. However, the regulatory body already received documentations from GSK long before the Nissen’s paper came out, according to WSJ.
CVD Journal News
The journal Circulation has dedicated a special issue on cardiovascular disease in Asia. “The presentation of disease there [in Asia] is often different from that seen in the West, and responses to treatment can also differ, necessitating separate study in Asian populations. And given that it is now widely acknowledged that 85% of cardiovascular deaths worldwide will soon occur in low- and middle-income countries, there is a pressing need for such research.”
CVD Regulatory News
The US FDA is finally done with reviewing the controversial data of the ENHANCE and issued a statement that Vytorin and other cholesterol-lowering drugs stay, at least for the moment. Vytorin is a combination of the two drugs ezetimibe/simvastatin, which although significantly lowered LDL-cholesterol levels, “did not translate into a significant improvement in carotid IMT.” Results of a similar study IMPROVE IT are being awaited in 2012.
Photo credit: stock.xchng